3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
6
Gastrointestinal
3
CNS
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Wilms Tumor
1
Testicular Germ Cell Tumor
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hepatic Veno-Occlusive Disease
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
28
Docetaxel
21
Gemcitabine
19
Nivolumab
15
Paclitaxel
13
Prednisone
12
Leuprolide
11
pazopanib
10
Radiotherapy
10
Cisplatin
10
Sunitinib
9
Sorafenib
9
Ipilimumab
8
Blood Specimen Collection
8
Bevacizumab
8
avelumab
7
atezolizumab
7
Therapeutics
7
Thalidomide
7
Cyclophosphamide
7
Carboplatin
7
Standard of Care
6
Radiation
6
Mitomycin
6
Interleukin-2
6
Cetuximab
6
Axitinib
6
padeliporfin
5
enzalutamide
5
cemiplimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Hematologic Tests
×
Genitourinary
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled